N-Methyl-3-isopropyl-succinimid | 15542-99-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Methyl-3-isopropyl-succinimid
• 英文别名: 3-isopropyl-1-methyl-pyrrolidine-2,5-dione；3-isopropyl-N-methylsuccinimide；1-methyl-3-propan-2-ylpyrrolidine-2,5-dione
• CAS: 15542-99-1
• 化学式: C₈H₁₃NO₂
• 分子量: 155.197
• InChiKey: LUOKEEIOPMUJLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
  申请人：Medimmune Limited

  公开号：US20180134717A1

  公开（公告）日：2018-05-17

  Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.

  揭示了用于制备通过N10位置连接的PBD分子的共轭物和化合物，以及利用这些共轭物治疗增殖性疾病，包括癌症。
• [EN] SILANOL BASED THERAPEUTIC PAYLOADS<br/>[FR] CHARGES UTILES THÉRAPEUTIQUES À BASE DE SILANOL
  申请人：BLINKBIO INC

  公开号：WO2017214491A1

  公开（公告）日：2017-12-14

  Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.

  本文部分描述了基于硅醇的治疗载荷，包括硅醇末端、二价间隔基团和能够影响靶细胞或组织的药物基团。
• SEMISYNTHETIC DERIVATIVES OF NYSTATIN A1
  申请人：BLIRT S.A.

  公开号：US20150045316A1

  公开（公告）日：2015-02-12

  The invention provides semisynthetic derivatives of Nystatin A 1 , water soluble salts and complexes, pharmaceutical compositions and plant protection products comprising the derivatives and their use, as antifungal antibiotics (Formula 1a).

  这项发明提供了Nystatin A1的半合成衍生物，水溶性盐和络合物，包括这些衍生物的药物组合物和植物保护产品，以及它们作为抗真菌抗生素的用途（公式1a）。
• Multifunctional linker technology containing an N4 group
  申请人：The Board of Regents of the University of Texas System

  公开号：US10441607B1

  公开（公告）日：2019-10-15

  In some aspects, the present disclosure provides compositions comprising an N4-based MMC ligand, a cell targeting group, and a fluorophore or a therapeutic compound comprising a formula: wherein the variables are as defined herein. In some embodiments, these compositions may be used in the imaging techniques or in the treatment of a disease or disorder such as cancer.

  在某些方面，本公开提供包含基于N4的MMC配体、细胞靶向基团和荧光团或治疗化合物的组合物，其化学式如下：其中变量如本文所定义。在某些实施方式中，这些组合物可用于影像技术或治疗癌症等疾病或疾病的治疗。
• PROTEIN AND PROTEIN CONJUGATE FOR DIABETES TREATMENT, AND APPLICATIONS THEREOF
  申请人：ADDA Biotech Inc.

  公开号：US20150183847A1

  公开（公告）日：2015-07-02

  The present invention relates to the field of biopharmaceutics, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in a marked reduction in side effects.

  本发明涉及生物制药领域，特别是一种蛋白质、蛋白质结合物、制药组合物及其治疗糖尿病的用途。本发明的融合蛋白质是通过连接两个多肽而获得的，其中一个多肽是白细胞介素-1受体拮抗蛋白或类似物，另一个多肽是GLP-1受体结合多肽或类似物，或胰岛素受体结合多肽或类似物，或GIP受体结合多肽或类似物。本发明的融合蛋白质及其结合物在治疗糖尿病方面具有显著的疗效，并且可以以较低剂量使用，从而显著减少副作用。